论文部分内容阅读
Background TARGET Ⅰ randomized controlled trial demonstrated that the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort Medical,Shanghai,China) was non-inferior to the everolimus-eluting stent with respect to in-stent late loss at 9 months for the treatment of single de novo coronary lesions.